- Why Cryoport
- Who We Serve
- About Us
- News & Events
- Investor Relations
- Contact Us
With today’s research collaboration, supply chain distribution, clinical and commercial programs spanning across continents, it is essential for pharmaceutical or biotechnology companies to safely ship cryogenic and temperature-controlled bio-specimen and therapies across countries or oceans, so they can leverage the entire value chain to conduct pioneering research or treat illnesses.
In December 2016 the US Congress enacted the 21st Century Cures Act, which required the FDA to facilitate an efficient development program for, and expedite the review of, new medicines meeting the definition of a regenerative advanced therapy (RAT) (Section 3033). The RAT designation in the legislation is now referred to as the Regenerative Medicine Advanced Therapy (RMAT) designation.
Now that the first two of these therapies have been approved, the supply chain of patient- and donor-derived regenerative medicine products will fall under increasing pressure for standardization and increased regulatory requirements. Much of the early regulatory focus has been on material processing with four guidance documents issued in a regulatory framework established by the FDA on November 16, 2017, its focus is on recovery, isolation, and delivery. Cryoport believes that enhanced traceability within the temperature-controlled and cold chain logistics distribution will also be subjected to additional regulatory requirements due to the fragile aspect of the drug product and the disproportionate risk of improper cold chain management on the viability of the therapies.